Argent BioPharma (ASX:RGT) has announced the results of an independent in vivo study evaluating the efficacy of ArtemiC, the USA OTC Unlicensed Drug Brand name of CimetrA, its lead immunomodulatory therapeutic, in a severe viral inflammatory model targeting Acute Respiratory Distress Syndrome. …
Latest Video
New Stories
-
Vaxxas secures $90 million in funding to commercialise needle-free vaccination delivery technology
August 25, 2025 - - Australian Biotech -
Botanix appoints Dr Patricia Walker as a non-executive director
August 25, 2025 - - Australian Biotech -
First site initiated for Neuren’s Phelan-McDermid syndrome Phase 3 trial
August 25, 2025 - - Australian Biotech -
Argent BioPharma announces results of independent in vivo study
August 25, 2025 - - Australian Biotech -
An outcome that might haunt the system's decision-making, like Banquo's ghost
August 25, 2025 - - Latest News -
Disappointment as committee stalls again on broad listing for cancer immunotherapies
August 25, 2025 - - Latest News -
PBAC delivers recommendations dominated by price cuts and risk shares
August 25, 2025 - - Latest News